Clinical Trial Detail

NCT ID NCT02571725
Title PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
Recruitment Recruiting
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors New Mexico Cancer Care Alliance
Indications

peritoneal carcinoma

ovarian carcinoma

fallopian tube carcinoma

Therapies

Olaparib + Tremelimumab

Age Groups: senior adult

No variant requirements are available.